Sanofi Options First Recursion Immunology Candidate

Sanofi has optioned the first development candidate from its multi-programme research collaboration with Recursion Pharmaceuticals, the Salt Lake City AI drug-discovery company said on 15 October 2026.

The option triggered a $10 million milestone payment to Recursion. That brings total upfront and milestone payments received from Sanofi under the collaboration to $144 million, Recursion said. Recursion is eligible for more than $300 million in additional milestones under the programme, with double-digit royalties on net product sales if a medicine is approved. Those further milestones and royalties are potential only; they depend on later success and commercialisation.

What was optioned

Recursion described the asset as a potential first-in-class oral small molecule designed against a challenging dual target implicated in inflammatory disease. “Potential first-in-class” is the company’s framing; the specific molecular target was not disclosed.

According to the release, optimising for that target pair meant navigating complex and competing chemistry constraints to balance drug-like properties. Recursion said the candidate came from combining its AI-enabled drug-design platform and small-molecule chemistry with Sanofi’s drug-discovery and immunology expertise, using iterative cycles of prediction, chemical design, synthesis and experimental validation.

Development plans

The candidate has been added to Sanofi’s development pipeline. A Phase 1 clinical study is currently planned to begin in 2027, with Sanofi funding and leading further development and commercialisation. “Currently planned” is forward-looking language: trial starts can slip, and Recursion’s own forward-looking statements warn that collaborators may delay, deprioritize or discontinue programmes.

Recursion said the $10 million milestone will be recognised as revenue in the third quarter of 2026 and that the option ends Recursion’s operational requirements on this candidate, with future payments under the programme resulting in profit to Recursion.

What the executives said

Najat Khan, president and chief executive of Recursion, said: “The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines. Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline.”

Alyssa Johnsen, therapeutic area head for development in immunology and inflammation at Sanofi, said the companies “were able to move with speed and precision in a space where that balance is notoriously hard to achieve,” and that the candidate “has potential to deliver a differentiated oral medicine with highly selective dual targeting” for people with inflammatory diseases who still lack adequate options. That is Sanofi’s view of potential, not a completed clinical result.

Collaboration scorecard

Recursion said the collaboration was set up to discover and advance a portfolio of potentially first- and best-in-class small molecules across immunology and oncology. With this option, the collaboration has now achieved six progress-based milestones across five programmes.

Over the next 12 months, Recursion said other programmes in the joint portfolio have the potential to reach development-candidate and other progress-based milestones. That, too, is potential rather than guaranteed.

Why the money structure matters

Readers often see collaboration headlines that add every possible milestone into one large figure. Here the structure is clearer in stages:

Already received (per Recursion): $144 million in total upfront and milestones from Sanofi under the collaboration, including this $10 million option payment.
Still potential under this programme: more than $300 million in additional milestones, plus royalties if a product is approved and sold.
Near-term clinical gate: Phase 1 planned for 2027, funded and led by Sanofi.

Until a drug clears clinical and regulatory hurdles, the larger eligibility numbers remain contingent.

Why it matters

Optioning a development candidate is a stronger signal than signing a discovery alliance alone: Sanofi is choosing to put a specific molecule into its own pipeline. For Recursion, it is evidence the company can cite that its platform produced something a large pharma partner wants to advance — while still leaving efficacy, safety and approval entirely unproven.

Inflammatory disease is a crowded field. An oral dual-target profile, if it works, could matter for patients who prefer pills to injections, but that sentence stays conditional until human data exist.

What’s still unknown

The identity of the dual target and the disease indications Sanofi will pursue first.
Exact Phase 1 timing, sites and design.
How the “more than $300 million” additional milestones break down by event.
Whether Sanofi will keep the programme on the 2027 path.

What to watch

Watch Sanofi’s pipeline disclosures for a named asset from the Recursion collaboration, clinical-trial registry entries ahead of 2027, and any further development-candidate options from the other programmes Recursion says are advancing.

What this means

First option exercised. Sanofi has taken the first development candidate from the collaboration into its pipeline.
$10 million now; more is potential. Extra milestones above $300 million and royalties depend on later success.
Phase 1 is planned, not running. 2027 is the companies’ current plan.